Cognito Therapeutics today announced new data from its OVERTURE feasibility trial evaluating its Spectris neuromodulation ...

Q4 2024 Earnings Call Transcript March 31, 2025 Rani Therapeutics Holdings, Inc. misses on earnings expectations. Reported ...

Neurona will kick start a Phase III trial in H2 2025 investigating NRTX-1001 in patients with a type of drug-resistant ...

Talat Imran; Chief Executive Officer, Director; Rani Therapeutics Holdings Inc Svai Sanford; Chief Financial Officer; Rani Therapeutics Holdings Inc Welcome to the Rani fourth-quarter and full-year ...

Rapport Therapeutics focuses on developing specific small molecule therapies for CNS diseases. Check out my recommendation ...

James Cassella, Ph.D., Chief Development Officer of Trevi Therapeutics added ... for patients with moderate or severe baseline cough frequency. We look forward to advancing development of ...

The US Food and Drug Administration (FDA) has approved Qfitlia (fitusiran), the first antithrombin-lowering (AT) therapy for routine prophylaxis to prevent or reduce the frequency of bleeding episodes ...

A research group led by Takumi Kagawa and Masashi Kato at Nagoya University Graduate School of Medicine has discovered that ...

Researchers at the Institute of Automation of the Chinese Academy of Sciences have developed a compact, battery-powered brain ...

vibroacoustic therapy delivers low frequency sound waves (typically between 30 to 120 Hz) through specially designed tables, chairs, or beds equipped with transducers that convert sound into ...

One of the most crucial aspects of psychedelic therapy is the process of making meaning from psychedelic experiences and ...

Edgewise's EDG-7500 lowered LVOT gradient and NT-proBNP levels in HCM patients, improving symptoms. Initial Part D data is expected in late 2025.